Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04428333
Title Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

oropharynx cancer

laryngeal squamous cell carcinoma

head and neck squamous cell carcinoma

hypopharynx cancer

oral cavity cancer

Therapies

Carboplatin + Fluorouracil + Pembrolizumab

Cisplatin + Fluorouracil + GSK3359609 + Pembrolizumab

Cisplatin + Fluorouracil + Pembrolizumab

Carboplatin + Fluorouracil + GSK3359609 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.